Table 1 Clinicopathological features non-KIT exon 9 patients
Characteristics | Second-line: sunitinib, n (%) | Second-line: imatinib dose escalation, n (%) |
|---|---|---|
Number of patients | 72 | 38 |
Gender* | ||
Male | 43 (59.7) | 27 (71.1) |
Female | 29 (40.3) | 11 (28.9) |
Age at diagnosis, mean (SD)** | 61.2 (12.4) | 58.2 (12.7) |
Tumor size in cm, median (range) | 11.0 (3.0–35.0) | 12.0 (3.5–26.0) |
Stage at diagnosis | ||
Localized | 11 (15.3) | 6 (15.1) |
Locally advanced | 6 (8.3) | 4 (10.5) |
Metastasized | 54 (75.0) | 27 (71.1) |
Multiple localization | 1 (1.4) | 1 (2.6) |
Localization primary tumor*** | ||
Gastric | 40 (55.6) | 16 (42.1) |
Small bowel | 20 (27.8) | 12 (31.6) |
Duodenal | 2 (2.8) | 2 (5.3) |
Rectum | 1 (1.4) | 1 (2.6) |
Esophagus | – | 1 (2.6) |
Colon | 2 (2.8) | 1 (2.6) |
Pelvic cavity | – | 1 (2.6) |
Peritoneum | 1 (1.4) | 1 (2.6) |
Unknown | 6 (8.6) | 3 (7.9) |
Mitotic count† | ||
Low (≤ 5/50 HPF) | 32 (44.4) | 13 (34.2) |
High (> 5/50 HPF) | 23 (31.9) | 17 (44.7) |
Not reported | 17 (23.6) | 8 (21.1) |
Mutation†† | ||
KIT exon 11 | 47 (65.3) | 27 (71.1) |
KIT exon 13 | 4 (5.6) | 3 (7.9) |
KIT exon 17 | 1 (1.4) | 1 (2.6) |
PDGFRA exon 14 | – | 1 (2.6) |
PDGFRA exon 18, D842V | – | 1 (2.6) |
PDGFRA exon 18, non-D842V | 8 (11.1) | 3 (7.9) |
SDHA/SDHB mutation | 2 (2.8) | – |
WT KIT/PDGFR/SDH | 6 (8.3) | 2 (5.3) |
WT KIT/PDGFR | 4 (5.6) | – |
Duration first line imatinib, median (range)§ | 18.5 months (0.9–94.3) | 16.3 months (0.1–105.9) |